Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment

Xijun Chen, Qing Ye, Zhigao Chen, Qian Lin, Wen Chen, Chengrong Xie, and Xiaomin Wang

The Third Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China; Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China

ABSTRACT
Long non-coding RNAs are essential to hepatocellular carcinoma (HCC) development, progression, and incidence of drug resistance. However, the biological significance of long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) remains poorly characterized. In this study, we observed noticeable increased levels of MKLN1-AS in HCC tissues. This upregulation of MKLN1-AS was clinically associated with vascular invasion and decreased disease-free survival and overall survival of patients with HCC. Functionally, MKLN1-AS-knockdown dramatically suppressed the metastasis and growth of HCC cells in vitro and in vivo. Additionally, the knockdown of MKLN1-AS augmented the pro-apoptosis effect of lenvatinib. Taken together, our findings indicate that MKLN1-AS may be exploited as a potential prognostic predictor and therapeutic target for HCC treatment.

ARTICLE HISTORY
Received 22 February 2022
Revised 29 April 2022
Accepted 2 May 2022

KEYWORDS
Long non-coding RNAs; hepatocellular carcinoma; MKLN1-AS; proliferation; lenvatinib; prognosis; therapeutic target

Highlights
- MKLN1-AS expression is elevated in HCC samples, which indicated a poor prognosis.
- MKLN1-AS promotes the malignant progression of HCC cells both in vitro and in vivo.
- MKLN1-AS knockdown significantly increased the efficacy of lenvatinib in HCC cells.

Introduction
Primary liver cancer is the fourth-leading cause of cancer-related mortality worldwide; about 80% of these are hepatocellular carcinoma (HCC) [1]. Although the prognosis of patients with early-stage HCC has significantly improved in recent years with surgical resection, chemotherapy, liver transplantation, catheter embolization, and percutaneous ablation treatment, the majority of patients who are diagnosed at the intermediate to the advanced stage are ineligible for these treatments, leading to poor treatment outcome [2]. Therefore, it is crucial to elucidate the mechanisms governing HCC progression to identify novel targets that inform effective therapeutic strategies.

Long non-coding RNAs (lncRNAs) are RNA transcripts longer than 200 nucleotides that do not encode proteins [3]. LncRNAs exert their functions in various ways, such as lncRNA-DNA, lncRNA-microRNA, and/or lncRNA–protein complexes.

CONTACT Chengrong Xie (eason_xiecr126.com); Xiaomin Wang (zy17689203@126.com) Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, 209 South Hubin Road, Xiamen, Fujian Province 361004, People’s Republic of China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
interactions [4]. LncRNAs are essential to HCC development, progression, and incidence of drug resistance [5,6], suggesting that LncRNAs could be potential diagnostic or therapeutic target candidates. For instance, the overexpression of LINC00624 leads to the dissociation of the HDAC6-TRIM28-ZNF354C transcriptional co-repressor complex, hastening the progression of HCC [7]. Another lncRNA, HULC cooperates with miR-15a to activate the AKT-PI3K-mTOR pathway by inhibiting PTEN in liver cancer, enabling the development of liver cancer [8].

Several bioinformatics studies have reported long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) as a valuable diagnostic factor and prognostic biomarker for HCC [5,6]. A recent study has revealed that MKLN1-AS could function as a molecular sponge to inhibit miR-654-3p [9]. Another study suggested that MKLN1-AS elevates ETS1 expression through sponging miR-22-3p [10]. These pathways promoted HCC progression. Additionally, MKLN1-AS fosters the progression of HCC by positively regulating YAP1 expression by targeting and stabilizing YAP1 mRNA [11]. However, to the best of our knowledge, no empirical evidence has suggested that MKLN1-AS could act as a candidate therapeutic target for HCC.

In this work, we aim to examine the clinical significance and functional role of MKLN1-AS in HCC and examine their potential as therapeutic targets. We found a significantly elevated MKLN1-AS in HCC samples, which indicated a poor prognosis. Additionally, our results reveal the cancer-promoting function of MKLN1-AS in HCC cells both in vitro and in vivo. Furthermore, knockdown MKLN1-AS significantly increased the efficacy of lenvatinib in HCC cells.

Materials and methods

Clinical sample collection

After institutional ethics clearance, the HCC tissue specimens were collected from the Biological Liver Cancer Sample Bank, Zhongshan Hospital of Xiamen University. The samples were gathered from 59 patients (aged 22–90 years) from 2017 to 2021. None of them received preoperative anti-tumor therapies. Clinical human HCC tissue samples were obtained and directly frozen in liquid nitrogen and stored at −75°C for further testing. All individuals signed a written informed consent document for all the procedures. The Ethics Committee of Zhongshan Hospital, Xiamen University, the informed consent form, and experimental procedures conform to the World Medical Association Declaration of Helsinki (Code: XMSZYY-SC-12-03). Follow-up information was collected by reviewing patients’ medical records and telephone contact.

Cell culture

MHCC97-L, MHCC-97 h, Li7, SK-Hep-1, Hep3B, Huh-7, and PLC/PRF/5 cells were purchased from Shanghai Cell Bank, Chinese Academy of Sciences. Cells were all cultured in the DMEM (Vivacell, Biosciences, Shanghai, China) supplemented with 10% fetal bovine serum (FBS, Vivacell, Biosciences, Shanghai, China) and Penicillin/streptomycin (100×) at 37°C with 5% CO₂.

RNA extraction and quantitative real-time PCR (qPCR)

The total RNA was extracted using Trizol reagent (Invitrogen, USA) following the manufacturer’s instructions. The cDNA was synthesized using Evo M-MLV RT Kit for qPCR II (Accurate Biotechnology, Shanghai, China). The RT-PCR was performed adopting SBYR Green qPCR Kit (Accurate Biotechnology, Shanghai, China) in a Light-cycler 96 PCR detection system. The specific qPCR primer sequences were used as follows:

MKLN1-AS-forward: 5'-GATAACCGTCCAGGAATGAGAG-3';
MKLN1-AS -reverse: 5'-CCCAGCCACAAACAAATAAA-3';
GAPDH-forward: 5'-GGAGCGGAGATCCCTCCAAAAT-3';
GAPDH-reverse: 5'-CCCAGCCACAAACAAATAAA-3';
GGCTTGTGTCATACCTCTCAGG-3';
U6-forward: 5'-CTCGCTTCGGCAGCACA-3';
U6-reverse: 5'-AACGCTTCACGAATTTGCGT-3';
ACTB-forward: 5'-GGACACGAGCAATGAAG-3';
ACTB-reverse: 5'-CCGATCCACACGGAGTACTTG-3';
Transfection

For MKLN1-AS knockdown, the targeting MKLN1-AS smart silencer and negative control smart NC-silencer were chemically synthesized from Ribobio Company (Guangzhou, China). Human RiboTM IncRNA Smart Silencer for MKLN1-AS is a pool including three independent siRNA and three independent antisense oligonucleotides

siRNA target sequence-1: 5’-GCCCTGGACAGTGTCATCATC-3’;
siRNA target sequence-2: 5’-ACAAGCAGAGCCACTGCAGT-3’;
siRNA target sequence-3: 5’-TGGCCTGGTCCCTTGTCTAC-3’;

The SK-Hep-1 and Huh-7 cells were inoculated at a density of 65% onto 6-well plates. The following day, we mixed lipofectamine RNAiMAX (Invitrogen, Carlsbad), MKLN1-AS smart silencer/smart silencer -NC, and Opti-MEM according to the instruction. Thirty-six hours later, cells were used for further investigation.

Construction of stable cells with MKLN1-AS knockdown

To get an MKLN1-AS stable knockdown Huh-7 cell line, a shRNA sequence was inserted into the PLV-shRNA-mcherry-puro plasmid. The shMKLN1-AS target sequence was as follows: 5’-GGAGTAAGTCAGCAGGATTCA-3’. As mentioned above, the negative control and vectors that expressed lentivirus were co-transfected into 293 T cells with the pMD.2 G (envelope) and psPAX2 plasmid (packaging). After 48 h post-transfection, supernatants containing lentiviral particles were collected. Huh-7 cell was infected with an empty vector and MKLN1-AS lentiviral particles with 5 μg/mL polybrene (Sigma-Aldrich, USA). Then, 2 μg/mL puromycin (Biosharp, Shanghai, China) was used to select stable cells.

Migration and invasion assays

Transwell migration (without Matrigel) and Matrigel invasion assays evaluated cell migration and invasion capacities, respectively. For migration detection, 1 × 10^5 cells resuspension in the base medium (200 μL) were loaded into the upper chamber without Matrigel. For invasion assay, 1.8 × 10^5 cells resuspension in the base medium (200 μL) were loaded to each upper insert; each upper insert needed was precoated with Matrigel. In the matched lower chamber, the base medium (500 μL) containing 10% FBS was added. After 36 h of incubation, a cotton swab was applied to remove cells from the upper surface of the transwell membrane. In contrast, cells that had migrated (or invaded through the Matrigel) to the lower side of the membrane were fixed with 4% poly-methanol, staining with 0.1% crystalline violet, and finally counting of five random areas of each insert under 20x magnification.

Wound-healing migration assay

Once the cells reached 90–95% confluence in the 6-wells culture plate, artificial lines were generated using a sterile 200ul plastic pipette tip in each cultured well. The cellular debris was removed by three washes using warm PBS. Images were obtained using a microscope at 0 h, 24 h, and 48 h, and cell migration capacity was measured by the percentage of the healed area to the starting wounded area using the Image J software.

Proliferation assays

For cell proliferation analysis, CCK8 (Dojindo, Japan) reagent was used following the user manual. HCC cells were seeded into 96-well plates at 2.5 × 10^3 cells/well. At each indicated time point, CCK-8 reagent (10 μL) was added to each well. One hour later, fluorescence at 450 nm was measured.

Colon formation

A total of 2.5 × 10^3 cells were loaded into 6-well plates for about 2 weeks. It is then fixed with 4% paraformaldehyde for 20 min, and then stained with 1.0% crystal violet for 15 min until formed visible clones.

Nuclear/cytoplasmic fractionation

Cytoplasmic and nuclear fractions were been extracted using a Cytoplasmic & Nuclear RNA
Purification Kit according to the user manual (Norgen Biotek Corp, CA). Then qPCR was applied to detect the MKLN1-AS expression in cytoplasmic and nuclear fractions.

**Annexin V and PI staining**

HCC cells were washed with warm PBS and trypsin, detached with trypsin and resuspended in an apoptosis detection kit following the manufacturer’s instructions (Dojindo, Kumamoto, Japan). Cells were analyzed by flow cytometry on Beckman Coulter Gallios Flow Cytometer (Beckman Coulter, Mississauga, Ontario, Canada). Kaluza software was used to make dot plots and analyze the results (Mississauga, ON, Canada).

**Fluorescence in situ hybridization**

The fluorescence in situ hybridization (FISH) assay was conducted using red Servicebio lncRNA FISH Probe Mix (Servicebio, China). Huh-7 cells were fixed on coverslips using 4% paraformaldehyde. The cells were permeabilized with 0.5% Triton X-100 for 20 minutes and dehydrated by ethanol. Proteinase K (20 μg/mL) (Servicebio, China) was added to digest for 20 min enzymatically. Next, a hybridization solution containing the MKLN1-AS lncRNA probe (10 ng/μL) was added, and the mixture was incubated at room temperature in the dark for 12 h. Nikon upright fluorescence microscope was used to observe the sections and take images (Nikon, Tokyo, Japan).

**Figure 1.** MKLN1-AS is up-regulated in HCC samples and related to poor prognosis.

(a) MKLN1-AS mRNA expression levels in HCC and normal liver samples from TCGA and GTEx databases. (b) Disease-free survival (DFS) rates and overall survival (OS) rates were analyzed based on TCGA and GTEx databases. (c) MKLN1-AS mRNA expression levels in 59 paired HCC samples and adjacent samples from our specimen bank were detected by qPCR (paired-samples t-test for N/T pairs analysis). (d) The overall survival (OS) and disease-free survival (DFS) in 59 patients with low (N > T) and high MKLN1-AS expression (N < T) were analyzed by Kaplan–Meier survival analysis.
Animal studies

Animal studies were approved by the ethical committee of Xiamen University, following the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Code: XMULAC20170162). A total of $4 \times 10^5$ control and shMKLN1-AS Huh-7 cells were inoculated subcutaneously into both sides of the backs of the BALB/c nude mice. The BALB/c mice were sacrificed 5 weeks later, and the subcutaneous tumors were harvested to compare the tumor weight and volume.

Statistical analysis

All cell experiments were repeated three times. The experimental data were performed using SPSS software, version 23.0 (IBM Corporation, New York, USA). The data are expressed as mean ± standard deviation (SD). The student’s $t$-test was used for two related samples within groups to compare variables. The Chi-square test examined the relationship between the MKLN1-AS expression and HCC patients’ clinicopathological factors. The $p$-value lower than 0.05 was considered to be statistically significant.

Results

MKLN1-AS is highly expressed in HCC samples of patients with poor prognosis

To establish the clinical significance of MKLN1-AS expression in HCC, we used the GEPIA2 web server (http://gepia2.cancer-pku.cn/#index) from the TCGA and GTEx databases. The analysis confirmed that MKLN1-AS is significantly overexpressed in HCC samples (Figure 1(a)). Additionally, the Kaplan–Meier analysis indicated that the high expression of MKLN1-AS is significantly correlated with short disease-free survival (DFS) and overall survival (OS) (Figure 1(b)). Furthermore, we evaluated the MKLN1-AS levels in 59 paired HCC samples and adjacent non-cancerous samples using qPCR. The results showed that the MKLN1-AS levels in 59 paired HCC samples are higher than in non-cancerous samples (Figure 1(c), $p < 0.05$). Moreover, the Kaplan–Meier analysis suggested that the higher expression of MKLN1-AS is strongly correlated with shorter overall survival and disease-free rates (Figure 1(d)). We analyzed the correlation between the expression of MKLN1-AS and clinicopathological features.

The MKN1-AS levels are not significantly correlated with gender, age, tumor size, differentiation, satellite foci, AFP level, quantification of hepatitis B virus (HBV) DNA, or liver cirrhosis ($p > 0.05$). However, groups with high-level expression of MKLN1-AS exhibit more vascular invasion than those with low-level expression of MKLN1-AS (Table 1). Together, the MKLN1-AS is upregulated in HCC samples and indicates a poor prognosis in patients with HCC.

| Table 1. Correlation between MKLN1-AS score in HCC and clinicopathological factors. |
|--------------------------------|-----------------|-----------------|-----------------|-----------------|
| Clinicopathological factors   | High-expression | Low-expression | $P$-value       |
| Age (years)                   |                 |                 |                 |
| <60                           | 18              | 7               | 0.2962          |
| ≥60                           | 20              | 14              |                 |
| Sex                          |                 |                 |                 |
| Male                         | 33              | 15              | 0.1747          |
| Female                       | 5               | 6               |                 |
| Tumor size (cm)              |                 |                 |                 |
| ≤5                           | 22              | 11              | 0.7864          |
| >5                           | 16              | 10              |                 |
| Differentiation level        |                 |                 |                 |
| Low                          | 2               | 2               | 0.6389          |
| Medium                       | 32              | 18              |                 |
| High                         | 4               | 1               |                 |
| Satellite foci               |                 |                 |                 |
| With                         | 6               | 4               | 0.7128          |
| Without                      | 31              | 14              |                 |
| AFP (µg/L)                   |                 |                 |                 |
| <200                         | 21              | 11              | 0.7889          |
| ≥200                         | 16              | 10              |                 |
| Vascular invasion            |                 |                 |                 |
| With                         | 19              | 3               | 0.0043**        |
| Without                      | 18              | 18              |                 |
| HBV DNA (cps/mL)             |                 |                 |                 |
| ≥500                         | 19              | 9               | 0.7828          |
| <500                         | 18              | 11              |                 |
| Liver cirrhosis              |                 |                 |                 |
| Without                      | 10              | 5               | >0.9999         |
| With                         | 28              | 16              |                 |

N, Adjacent noncancerous liver tissue; C, Cancer tissue; AFP, Alpha-fetoprotein; HBV, Hepatitis B virus. (*$p < 0.05$)

Down-regulation of MKLN1-AS inhibits migration, invasion, and proliferation of HCC cells

To shed light on the functional role of MKLN1-AS in HCC, we studied the effect of down-
Figure 2. Down-regulation of MKLN1-AS inhibits migration, invasion, and proliferation of HCC cells.
(a) Nuclear/cytoplasmic fractionation combined with qPCR and FISH assay revealed the distribution of MKLN1-AS in HuH-7 cells. (b) Expression of MKLN1-AS in HCC cell lines was determined using qPCR (Data are normalized to Hep3B cells). (c) Down-regulation efficacy of MKLN1-AS in two HCC cell lines. Effectiveness was evaluated by performing qPCR. (d) Clone formation assay was conducted to assess the clone formation abilities of the control and MKLN1-AS knockdown HCC cells. (e) The proliferation ability of SK-Hep-1 and HuH-7 was determined by the CCK-8 assay. (f) The typical images of the wounding-healing assay for the control and MKLN1-AS knockdown SK-Hep-1 and HuH-7 cells. After 0 h, 24 h, and 48 h, the wound-healing area was measured in three randomly selected fields at 100× magnification. (g) The representative pictures of transwell assay for the control and MKLN1-AS knockdown SK-Hep-1 and HuH-7 cells. The cells were counted under the microscope in five randomly selected fields at 100× magnification. Data are presented as mean ± SD (n = 3, * = p < 0.05; ** = p < 0.01, *** = p < 0.001).
The regulation of MKLN1-AS levels in HCC cells. We first determined the intracellular localization of MKLN1-AS using a nuclear/cytoplasmic fractionation (Left) and FISH experiment (Right), which revealed that MKLN1-AS is mainly localized in the HCC cytoplasm (Figure 2(a)). We then predicted the downstream target of MKLN1-AS on the basis of ceRNA mode through online databases (RNAAct and Targetscan), which is shown in the supplementary materials.

Next, we measured the RNA expression level of MKLN1-AS in seven HCC cell lines using qPCR (Figure 2(b)). Considering the basal MKLN1-AS expression levels and transfection efficacy among these cell lines, SK-Hep-1 and HuH-7 cells were simultaneously transfected with (small interfering MKLN1-AS) si-MKLN1-AS. We confirmed the efficacy of the MKLN1-AS knockdown using qPCR (Figure 2(c)). To understand the biological function of MKLN1-AS, we performed colony formation assays that revealed that MKLN1-AS knockdown cells form significantly fewer and smaller colonies than the control cells (Figure 2(d)). We evaluated the effect of MKLN1-AS knockdown on the proliferative capacity of HCC cells using the CCK8 assay, which revealed that cells were transfected with si-RNA (si-MKLN1-AS) exhibited diminished proliferative capacity (Figure 2(e)). We confirmed the suppression of motility mediated by MKLN1-AS knockdown using a wounding healing assay (figure 2(f)). Furthermore, as evidenced by migration and invasion assays, knockdown of MKLN1-AS significantly decreases the ability of migration and invasion (Figure 2(g)). Our results reveal that MKLN1-AS facilitates migratory, invasive, and proliferative activities of HCC cells in vitro.

**MKLN1-AS knockdown significantly increases inhibitory effects of lenvatinib**

Lenvatinib, an oral small-molecule inhibitor of the multiple receptor tyrosine kinases, is approved in the US, EU, Japan, and China for the first-line treatment of patients with HCC [12]. The drug inhibits hepatocellular carcinoma cell growth by promoting apoptosis [13]. We investigated the effect of MKLN1-AS knockdown on lenvatinib-induced apoptosis. First, we measured the IC_{50} values of lenvatinib in HuH-7 and SK-Hep-1 cell lines at the end of 48 h; the IC_{50} was 9.282 µmol and 8.925 µmol (Figure 3(a)). Next, Annexin V and PI staining was used to detect the effect of MKLN1-AS knockdown on lenvatinib. Although MKLN1-AS knockdown increases the apoptosis of HCC cells induced by lenvatinib treatment, it is not significant. However, MKLN1-AS knockdown significantly promotes apoptosis induced by lenvatinib in SK-Hep-1 and HuH-7 cells (Figure 3(b)).

**MKLN1-AS facilitates HCC growth in vivo**

To confirm the oncogenic effect of MKLN1-AS in vivo, the control and MKLN1-AS-depleted HuH-7 cells were subcutaneously injected into the armpit of nude mice. We validated the knockdown efficiency of MKLN1-AS in xenografts using qPCR (Figure 4(a)). The MKLN1-AS short hairpin RNA (sh-MKLN1-AS) xenografted nude mice resulted in a significant loss of tumor weight and appreciably reduced tumor incidence (Figure 4(b, c)). Together, the results verified that MKLN1-AS enhances HCC growth in vivo.

**Discussion**

We found that the expression of MKLN1-AS was higher in HCC tissues than in the corresponding non-cancerous tissues. Additionally, up-regulation of MKLN1-AS was positively correlated to vascular invasion, which suggested that MKLN1-AS may act as a tumor-promoting factor. Moreover, high expression of MKLN1-AS predicted poor overall survival (OS) and recurrence-free survival (DFS). We characterized the biological function of MKLN1-AS using functional experiments. The knockdown of MKLN1-AS decreased the migration, invasion, and in vitro cell proliferation abilities, and slowed in vivo tumor growth. Therefore, our results confirm that MKLN1-AS plays an oncogenic role in HCC.

Recent studies have revealed that MKLN1-AS aggravates HCC progression and can be a prognostic marker for HCC [9,11]. However, to the best of our knowledge, this is the first study to report MKLN1-AS as a potential therapeutic target. We confirmed this using MKLN1-AS-
Figure 3. MKLN1-AS knockdown enhances the inhibitory effects of lenvatinib in HCC cells.
(a) The IC50 values of lenvatinib in HuH-7 and SK-Hep-1 at 48 h were assessed by CCK-8 assay. (b) The histogram represents the percentage of cells found in the living (Annexin V− & PI−), early apoptotic (Annexin V+ & PI−), late apoptotic (Annexin V+ & PI+), and necrotic (Annexin V− & PI+) populations from SK-Hep-1 and HuH-7 treated with lenvatinib. The apoptosis of HCC cells was measured using the flow cytometry assay.
knockdown, which showed a significant decrease in the malignant biological function of HCC cells. Next, we measured the effectiveness of MKLN1-AS-knockdown in combination with lenvatinib, an oral molecule multi-kinase inhibitor in patients with unresectable HCC whose antitumor activity has been demonstrated in vitro and in vivo [14,15]. Lenvatinib significantly improved the outcome of patients with unresectable HCC [12]. Additionally, lenvatinib in combination with other treatments has demonstrated improved treatment response [16,17]. We performed the knockdown of MKLN1-AS using small-interfering RNA (siRNAs) [18,19] and used it in combination with lenvatinib treatment. Remarkably, we found that combined treatment enhanced apoptosis in HCC cells to MKLN1-AS knockdown or lenvatinib treatment alone. This suggests that knocking down MKLN1-AS increases the efficacy of lenvatinib. An article reports that targeting CD73 reverses lenvatinib resistance in HCC through downregulation of SOX9 [20]. Additionally, the silencing of SOX9 in HCC reduces MKLN1-AS expression [21]. Therefore, the function of CD73/SOX9/MKLN1-AS axis may play an essential role in lenvatinib treatment for HCC. This confirms that MKLN1-AS may serve as a future therapeutic target for patients with HCC.

The nuclear/cytoplasmic fractionation experiment and FISH assay revealed that MKLN1-AS is predominately expressed in the cytoplasm. Although lncRNAs are more abundant in the nucleus, numerous works have suggested that cytoplasmic lncRNAs are more abundant than previously thought [4]. Additionally, evidence reveals that cytoplasmic lncRNAs may act through lncRNA-RNA interaction. For example, the well-known lncRNA HOTAIR acts as a competitive endogenous RNA (ceRNA) for miR-331-3p to regulate the expression of HER2 in gastric cancer [22]. A recent study shows it upregulated long non-coding RNAs H19 and HULC sponging let-7a/let-7b and miR-372/miR-373 to regulate cholangiocarcinoma cell migration and invasion [23]. This leads us to hypothesize that the underlying mechanism of

Figure 4. MKLN1-AS facilitates HCC growth in vivo.
(a) Transfection efficiency of sh-MKLN1-AS in HuH-7 cells was confirmed by qPCR. (b) The tumor weight of xenograft from sh-MKLN1-AS and control HuH-7 cells was calculated. c. The representative images of sh-MKLN1-AS and control xenografts were imaged. Mice were injected with HuH-7 cells (n = 6).
MKLN1-AS regulating HCC development may be through the ceRNA mechanism. However, underlying mechanism necessitates further experimental studies.

**Conclusion**

In summary, our study proves that MKLN1-AS is an oncogenic lncRNA that promotes HCC cells migration, invasion, and proliferation and can be exploited as a potential therapeutic target for HCC treatment.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the National Natural Science Foundation of China [NO. 81871961, 81871963, 81802344]; Medical and Health Key project of Xiamen [3502ZZ20191106].

**Compliance with ethical standards**

All animal experiments were approved by the ethical committee of Xiamen University and under the Guide for the Care and Use of Laboratory Animals by NIH. This study was approved by the Ethics Committee of Zhongshan Hospital of Xiamen University and followed the clinical research guidelines.

**Authors’ contributions**

All authors contributed to data analysis, drafting or revising the article, finalizing the version to be published, agreeing to the submitted journal, and being accountable for all aspects of the work.

**Availability of data and materials**

The datasets used during this research are available.

**References**

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

[2] Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.

[3] Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–286.

[4] Bridges MC, Daulagala AC, Kourtidis A. LNCcation: LncRNA localization and function. J Cell Biol. 2021;220(2). DOI:10.1083/jcb.202009045

[5] Wu ZH, Li ZW, Yang DL, et al. Development and validation of a pyroptosis-related long non-coding RNA signature for hepatocellular carcinoma. Front Cell Dev Biol. 2021;9:713925.

[6] Deng X, Bi Q, Chen S, et al. Identification of a five-autophagy-related-lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma. Front Mol Biosci. 2020;7:611626.

[7] Li Z, Lu X, Liu Y, et al. Gain of LINC00624 enhances liver cancer progression by disrupting the histone deacetylase 6/Tripartite Motif containing 28/Zinc Finger protein 354C corepressor complex. Hepatology. 2021;73(5):1764–1782.

[8] Xin X, Wu M, Meng Q, et al. Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a. Mol Cancer. 2018;17(1):94.

[9] Gao W, Chen X, Chi W, et al. Long non-coding RNA MKLN1-AS aggravates hepatocellular carcinoma progression by functioning as a molecular sponge for miR-654-3p, thereby promoting hepatoma-derived growth factor expression. Int J Mol Med. 2020;46(5):1743–1754.

[10] Pan G, Zhang J, You F, et al. ETS Proto-Oncogene 1-activated muskelin 1 antisense RNA drives the malignant progression of hepatocellular carcinoma by targeting miR-22-3p to upregulate ETS Proto-Oncogene 1. Bioengineered. 2022;13(1):1346–1358.

[11] Guo C, Zhou S, Yi W, et al. Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) is a potential diagnostic and prognostic biomarker and therapeutic target for hepatocellular carcinoma. Exp Mol Pathol. 2021;120:104638.

[12] Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma. Drugs. 2019;79(6):665–674.

[13] Zheng Y, Huang C, Lu L, et al. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J Hematol Oncol. 2021;14(1):16.

[14] Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641–2653.

[15] Ogasawara S, Mihara Y, Kondo R, et al. Antiproliferative effect of lenvatinib on human liver cancer cell lines in vitro and in vivo. Anticancer Res. 2019;39(11):5973–5982.

[16] Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus Pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–2992.

[17] Gaspar N, Venkatramani R, Hecker-Nolting S, et al. Lenvatinib with etoposide plus ifosfamide in patients
with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021;22(9):1312–1321.

[18] Kulkarni JA, Witzigmann D, Chen S, et al. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res. 2019;52(9):2435–2444.

[19] Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977.

[20] Ma XL, Hu B, Tang WG, et al. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol. 2020;13(1):11.

[21] Guo C, Zhou S, Yi W, et al. SOX9/MKLN1-AS axis induces hepatocellular carcinoma proliferation and epithelial-mesenchymal transition. Biochem Genet. 2022. DOI: 10.1007/s10528-022-10196-6

[22] Liu XH, Sun M, Nie FQ, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer. Mol Cancer. 2014;13(1):92.

[23] Wang WT, Ye H, Wei PP, et al. LncRNAs H19 and HULC, activated by oxidative stress, promote cell migration and invasion in cholangiocarcinoma through a ceRNA manner. J Hematol Oncol. 2016;9(1):117.